{"The claim is based on a preliminary estimate from the Congressional Budget Office": "CBO) regarding the potential impact of House Speaker Nancy Pelosi's drug pricing plan on research and development spending and the introduction of new drugs.", "The claim is made by the Pharmaceutical Research and Manufacturers of America": "PhRMA), a trade group representing the biopharmaceutical industry, which argues that limiting drug prices would reduce the incentive and ability of companies to develop life-saving medications.", "Experts contest the link between drug prices and pharmaceutical research and development": "suggesting that the claim's assertion may not be supported by sufficient data.", "The CBO estimates that": "over the next decade, there could be a reduction of between eight and 15 new drugs coming to market, which represents a potential loss of around 5% out of the projected 300 drug approvals over the same period."}